BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price was down 3.8% during mid-day trading on Thursday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their price objective on shares of BriaCell Therapeutics from C$18.00 to C$15.00 in a research note on Thursday, September 19th.
Get Our Latest Stock Report on BCT
BriaCell Therapeutics Trading Down 3.8 %
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- How to invest in marijuana stocks in 7 steps
- Battle of the Retailers: Who Comes Out on Top?
- Investing In Automotive Stocks
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.